All News
CatenaBio Presents Poster on Multi-Payload Conjugates at the American Association for Cancer Research (AACR) Annual Meeting
April 8, 2024 San Diego, CA
ADCs have had tremendous impact on patient outcomes. However, many patients fail to respond or relapse after treatment with ADC therapies. Here we show a novel conjugation system capable of attaching distinct payloads at different sites to the same antibody, enabling the production of stable single molecule targeted combination therapies, Multi-Payload Conjugates, with a well-defined drug-antibody ratio.
CatenaBio Selected to Present on its Next Generation Platform and Multi Payload Conjugates (MPC®) at the Berkeley Bio Startup Showcase @JPM
January 4, 2024 Berkeley, CA
Presentation will include recent data shared at the San Antonio Breast Cancer Symposium showcasing the combination of multiple cell-killing mechanisms in a single MPC® built using the company’s proprietary CysTyr® platform.
Catena Biosciences Expands Executive Leadership Team, Appoints Saurabh Johri as Chief Business Officer and Rick Kendall as Chief Scientific Officer
July 27, 2023 Berkeley, CA
Catena Biosciences, Inc., a biotechnology company pioneering protein conjugation technologies for novel therapeutic development, today announced the expansion of its leadership team with two new executive appointments. The company has appointed Saurabh Johri as Chief Business Officer and Rick Kendall, Ph.D. as Chief Scientific Officer.